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A b s t r a c t
Introduction: Triple anticoagulation therapy (TT), comprising dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC), is 
essential in atrial fibrillation (AF) patients after percutaneous coronary intervention (PCI), but it increases the bleeding risk.
Aim: To assess TT models, in- and out-hospital bleeding and thromboembolic complications, and TT alterations.
Material and methods: During 12 months, consecutive AF post-PCI patients were scheduled for TT. Alterations in TT and throm-
boembolic events (death, myocardial infarction, ischemic stroke, in-stent thrombosis, peripheral embolization) were recorded. Major, 
non-major and minor bleeding episodes were assessed.
Results: One hundred and thirty-six out of 3171 patients, aged 73.0 ±8.4 years (90 male), were included. Intra-hospitally, 
thrombotic events occurred in 9 (6.6%), while bleeding events occurred in 71 (52.2%) patients. Access-site hematoma and blood 
transfusions during in-hospital stay predisposed physicians to heparin administration as part of TT on discharge (p = 0.018 and 
p = 0.033 respectively). Eventually, DAPT plus warfarin or plus novel oral anticoagulant (NOAC) or plus low molecular weight heparin 
was prescribed in 72 (52.9%), 53 (39%), and 11 (8.1%) patients, respectively. HAS-BLED and CHA2DS2-VASc scores were similar 
between subgroups (p = 0.63 and p = 0.64 respectively). During 10.2 ±4.2 months of follow-up, 11 (8.1%) deaths, and 9 (6.6%) 
non-fatal thromboembolic events occurred. Bleeding events occurred in 45 (34.6%) patients, including 14 (10.3%) major. TT was the 
only factor associated with increased risk of major bleeding (18.6% vs. 4.2%, p = 0.008). Early termination of any TT component, 
which concerned 59 (45.4%) patients, did not increase the risk of thromboembolic events (p = 0.89).
Conclusions: Our study indicates that TT is associated with high mortality and bleeding rates in a relatively short period of time. 
Discontinuation of any TT drug did not increase the thromboembolic event rate, while it was associated with reduced risk of major 
bleeding.
Key words: atrial fibrillation, cardiovascular events, triple anticoagulant therapy, coronary percutaneous intervention, bleeding 
and thromboembolic complications.
Introduction
Atrial fibrillation (AF) is the most common arrhyth-
mia, affecting an estimated 6 million Europeans [1], and 
it increases the risk of ischemic stroke (IS) five fold [1, 2]. 
Ischemic stroke of such etiology is proved to be associ-
ated with worse neurological outcomes compared to IS 
of other origin [1, 2]. It is reported that about 20–30% of 
all AF patients suffer from coronary artery disease (CAD) 
[3, 4] and subsequently face the need of percutaneous 
coronary intervention (PCI) with stent implantation. With 
AF being the most frequent indication for oral anticoagu-
lation (OAC) and PCI resulting in the need of lengthy dual 
antiplatelet therapy (DAPT), triple therapy (TT) seems to 
be the right choice for AF patients undergoing PCI [5]. 
However, it is uncertain which type of OAC should be 
combined with DAPT in which patients. Currently, there 
are three types of OAC therapy: vitamin K antagonists 
(VKA, i.e. warfarin or acenocoumarol), novel OACs (NOACs, 
such as rivaroxaban, dabigatran or apixaban) and low 
molecular weight heparin (LMWH). There is little research 
available on how to guide the decision-making process 
regarding type of TT for individual patients. Moreover, 
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limited data have been published regarding real-life as-
sessment of safety and efficacy of various forms of TT in 
clinical practice.
Aim
The study aimed to determine the real-life prevalence 
of patients on TT and to evaluate doctors’ decisions on 
TT models (DAPT + VKA, DAPT + NOAC, DAPT + LMWH), 
as well as to assess in- and out-hospital bleeding and 
thromboembolic complications.
Additionally, the data regarding TT duration and any 
alterations to the anticoagulation regimen for each pa-
tient in the outpatient setting were analyzed.
Material and methods
Study group
Out of 3171 consecutive patients admitted to our de-
partment between 1.10.2014 and 30.09.2015, 163 (5.1%) 
required TT. Twenty-one subjects were excluded due to 
participation in blinded anticoagulant drug trials and 
6 due to mechanical valve prosthesis. Altogether, 136 pa-
tients (mean age: 73.0 ±8.4, range: 51–88 years, 90 men) 
with either paroxysmal or permanent non-valvular AF ad-
mitted for stable angina (SA) or myocardial infarction (MI) 
who underwent PCI were retrospectively evaluated for 
bleeding and thromboembolic complications during the 
in-hospital period as well as during long-term follow-up. 
The DAPT was introduced or continued according to 
the guidelines on PCI. The DAPT in all study participants 
consisted of 75 mg of aspirin and 75 mg of clopidogrel 
daily. There were no patients taking ticagrelor or prasu-
grel. The mean weekly dosage of VKA was 29.7 mg, and 
the median weekly dosage was 28  mg. Seventy-three 
percent of patients taking rivaroxaban had a lower dose 
(15 mg q.d.) and 83% of patients taking dabigatran were 
on a lower dose (110 mg b.i.d.). Antithrombotic therapy 
was continued or introduced during hospitalization ac-
cording to the guidelines on AF [1]. Thus, in all of these 
patients AF was the indication for VKA/NOAC, whereas 
PCI was the indication for DAPT. 
Exclusion criteria were: valvular AF, participation in 
blinded anticoagulant drug trials, mechanical valve as 
indication for VKA, patients requiring coronary artery by-
pass grafting, and lack of patient consent.
The study participants were further divided according 
to their administered anticoagulation regimen during the 
in-hospital stay:
–  group I consisted of 72 patients (age 73.3 ±7.7 years, 
70.8% male) with VKA as part of the TT;
–  group II consisted of 53 patients (age 72.5 ±9.2 years, 
58.5% male) with NOAC as part of the TT;
–  group III consisted of 11 patients (age 77.0 ±11.0, 
72.7% male) with LMWH as part of the TT.
The prevalence of conventional atherosclerosis risk 
factors (diabetes, hyperlipidemia, arterial hypertension, 
previous MI, PCI or coronary artery bypass graft (CABG)), 
type of AF (paroxysmal vs. persistent) as well as baseline 
laboratory and angiographic results were recorded. 
Follow-up stopped at the time of death or on May 1, 
2016, whichever came first. Data regarding in-hospital 
stay were gathered retrospectively based on medical re-
cords, whereas follow-up was performed in the form of 
phone surveys and dedicated hospital visits.
The study protocol was reviewed and approved by 
the local ethical committee. All the studied patients gave 
their informed consent for participation in the study. The 
study was performed in accordance with the Declaration 
of Helsinki.
Atrial fibrillation and risk assessment
Atrial fibrillation was diagnosed in accordance with 
the 2010 ESC guidelines [6]. Additionally, any trace of AF 
in medical documentation of the patient (either previous 
ECG exams or documented diagnosis) was considered 
sufficient to diagnose AF.
Bleeding and thrombotic risk was assessed individ-
ually for each patient using the standardized HAS-BLED 
and CHA2DS2-VASc scales [6, 7]. 
Coronary angioplasty and PCI procedure
Coronary angioplasty was performed from the radi-
al or femoral vascular access using the Coroscop system 
(Siemens AG, Munich, Germany) equipped with Quantcor 
version 4.0 quantitative analysis software. The procedure 
was performed in accordance with widely accepted stan-
dards and rules. The details of the procedure such as pre-
dilatation before stenting, use of plaque preparation, AG 
rotablation or cutting balloon as well as use of bare-met-
al stents (BMS) or drug-eluting stents (DES) were left to 
the discretion of the leading physician.
DAPT + OAC therapy duration
Duration of TT was preplanned according to com-
bined consensus guidelines from 2014 [8]. In brief, in the 
setting of PCI in patients with SA, if BMS was implanted 
TT was recommended for at least 1 month with gastric 
protection, followed by OAC (INR 2.0–2.5 if VKA) provided 
that HAS-BLED is lower than 3. In the case of high HAS-
BLED (3 or more), TT was recommended for 2–4 weeks, 
followed by OAC thereafter. When a  2nd generation 
DES was implanted, TT was recommended for at least 
3 months, followed by OAC and aspirin up to 12 months, 
then OAC (INR 2.0–3.0 if VKA) thereafter.
In the setting of MI, in patients with low bleeding 
risk (HAS-BLED < 3) TT was recommended for at least 
6 months followed by single antiplatelet therapy and low 
intensity OAC (INR 2.0–2.5 if VKA) up to 12 months, and 
then OAC thereafter (INR 2.0–3.0 if VKA).
In MI patients with high bleeding risk (HAS-BLED 
3 or more), TT was recommended for 4 weeks, followed 
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by single antiplatelet therapy and low intensity OAC (INR 
2.0–2.5 if VKA) up to 12 months, and then OAC thereafter 
(INR 2.0–3.0 if VKA).
Concomitant use of PPI is recommended per guide-
lines for GI protection [8, 9].
TT termination
Early termination was defined as the termination of 
any antiplatelet drug earlier than recommended by the 
treating cardiologist or termination of use of the antico-
agulant drug at any point.
Evaluation of bleeding complications
The bleeding classification was adopted from Bey-
er-Westendorf et al., who divided bleeding into three cat-
egories: major, non-major clinically relevant (NMCR) and 
minor [10].
The following criteria for major bleeding in non-surgi-
cal patients were applied: fatal bleeding and/or symptom-
atic bleeding in a critical area or organ, such as intracrani-
al, intraspinal, intraocular, retroperitoneal, intraarticular 
or pericardial, or intramuscular with compartment syn-
drome, and/or bleeding causing a fall in hemoglobin level 
of 2 g/l or more, or leading to transfusion of two or more 
units of whole blood or red blood cells.
In brief, NMCR was defined as any non-major bleed-
ing comprising hemodynamics or leading to hospitaliza-
tion, as well as epistaxis, gingival bleeding, hemoptysis 
lasting more than 5 min, macroscopic hematuria or any 
bleeding that had clinical consequences for the patient 
(i.e. medical intervention, unscheduled medical contact, 
temporary cessation of the drug).
Minor bleeding was defined as any overt bleeding not 
fulfilling the definition of major or NMCR bleeding [10].
Evaluation of thrombotic and cardiovascular 
complications 
During the mean observation period of 10.2 ±4.2 
months the incidence of cardiovascular death (CVD), MI, 
IS, in-stent thrombosis and peripheral embolization was 
recorded. 
Clinical classification of MI was adopted from Thy-
gesen et al. [11]. Diagnosis of IS was established by 
a neurologist to ensure reliability. Cardiovascular death 
was defined as a fatal IS, fatal MI or other CVD (i.e. any 
sudden or unexpected death unless proven as non-car-
diovascular on autopsy). 
The criteria for stent thrombosis were adopted from 
an academic research consortium (ARC) [12].
Statistical analysis
Continuous variables are presented as mean ± one 
SD, while categorical variables are expressed as frequen-
cies and percentages. Means of analyzed parameters 
across groups were tested with the analysis of variance 
(ANOVA) test, and frequencies were compared by the c2 
test for independence.
The normal distribution of studied variables was de-
termined by the Shapiro-Wilk test. Differences between 
mean values were verified using Student’s t test when 
the distribution of variables was normal, in other cases 
applying the Mann-Whitney U test. Cumulative event-free 
survival Kaplan-Meier curves including overall event-free 
survival, death, thrombotic and major bleeding events 
were calculated for patients on active TT.
Statistical analyses were performed with Statistica 12.0 
software. Statistical significance was assumed at p < 0.05.
Results
In-hospital period
Out of 136 subjects with AF, the indication for cor-
onary angiography with subsequent PCI was MI in 76 
(55.9%) and SA in 60 (44.1%) patients (Table I). Balloon 
angioplasty alone was performed in 4 (2.9%), a BMS was 
implanted in 6 (4.4%), and a 2nd generation DES in 118 
(86.8%) subjects. One-vessel PCI was performed in 100 
(73.5%), 2-vessel PCI in 24 (17.6%) and 3-vessel PCI in 
4 (2.9%) patients. Out of the remaining 8 patients, 4 with 
an occluded target vessel and late presentation to the 
Emergency Department (ED) outside the therapeutic 
window, and 4 with multivessel disease were qualified 
for optimal medical treatment by the decision of a multi-
disciplinary Heart Team.
In-hospital thrombotic events occurred in 9 (6.6%) pa-
tients. Out of those 9 patients 6 (66.6%) were discharged 
on TT with VKA, 2 (22.2%) on TT with NOAC and 1 (11.1%) 
on TT with LMWH (p = 0.72). Detailed information on 
in-hospital thrombotic complications is shown in Table II.
Patients with acute coronary syndrome suffered more 
frequently from thrombotic complications during hospi-
talization than elective patients, although the difference 
was not statistically significant (9.5% vs. 3.2%, p = 0.15).
In-hospital bleeding occurred in 71 (52.2%) of pa-
tients. Major, NMCR and minor bleeding occurred in 31 
(22.8%), 16 (11.8%) and 45 (33.1%) patients respectively. 
A detailed description of all in-hospital bleeding compli-
cations is provided in Table II.
In patients with access site hematoma, LMWH was 
significantly more frequently prescribed as part of TT as 
compared to other drugs (27.3% vs. 5.1% in VKA and 
1.9% in NOAC groups, p = 0.018). Patients requiring 
blood transfusions during hospitalization were more like-
ly to receive LMWH on discharge as part of TT, compared 
to other anticoagulants (18.2% vs. 1.4% in VKA and 1.9% 
in NOAC groups, p = 0.033). Anticoagulant selection was 
mainly based on the risk of bleeding and prior complica-
tions on certain anticoagulation regimens (Table II).
On discharge, 72 (51%) patients were assigned to TT 
including VKA + DAPT, 53 (39%) received NOAC + DAPT, 
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Table I. Baseline patient characteristics. Urgent admission was associated with prescribing LMWH as part of TT 
on discharge. Patients on VKA had significantly higher INR than non-VKA patients
Parameter Overall
(n = 136)
Group 1
(n = 72)
Group 2
(n = 53)
Group 3
(n = 11)
ANOVA between subgroups
Atrial fibrillation: 0.300
Paroxysmal 93 (68.4) 46 (63.9) 38 (71.7) 9 (81.8)
Permanent 43 (31.6) 26 (31.1) 15 (28.3) 2 (18.2)
CHA
2
DS
2
-VASc [points] 4.4 ±1.6 4.3 ±1.3 4.4 ±1.9 4.8 ±1.3 0.641
Median 4 4 4 5
HAS-BLED [points] 2.5 ±0.9 2.5 ±0.8 2.5 ±1.0 2.7 ±0.8 0.639
Median 2 2 2 3
Age [years] 73.3 ±8.6 73.3 ±7.7 72.5 ±9.2 77.0 ±11.0 0.286
Sex (male) 90 (66.2) 54 (70.8) 31 (58.5) 8 (72.7) 0.315
Admission: 0.048
Urgent (ACS) 76 (55.9) 37 (54.4) 29 (54.7) 10 (90.9)
Planned (SA) 60 (44.1) 35 (48.6) 24 (45.3) 1 (9.1)
Risk factors:
Hypertension 129 (94.9) 69 (95.8) 49 (92.5) 11 (100.0) 0.506
Hyperlipidemia 119 (87.5) 64 (88.9) 44 (83.0) 11 (100.0) 0.263
Diabetes mellitus 58 (42.6) 33 (45.8) 22 (41.5) 3 (27.3) 0.499
Previous MI 65 (47.8) 34 (47.2) 22 (41.5) 9 (81.8) 0.051
Previous PCI 53 (39.0) 31 (43.1) 17 (32.1) 5 (45.5) 0.415
Previous CABG 23 (16.9) 15 (20.8) 7 (13.2) 1 (9.1) 0.410
Laboratory data:
Creatinine [mg/dl] 106.3 ±71.0 115.0 ±94.1 91.9 ±20.8 117.1 ±27.7 0.176
eGFR [ml/min/1.73 m2] 66.4 ±19.8 66.0 ±22.5 69.2 ±14.9 55.7 ±18.9 0.118
HGB [g/dl] 13.5 ±1.4 13.5 ±1.2 13.5 ±1.5 13.0 ±2.2 0.448
PLT [109/l] 214.2 ±62.4 210.5 ±56.5 224.5 ±67.5 189.4 ±70.3 0.180
INR 1.4 ±0.6 1.6 ±0.7 1.1 ±0.2 1.2 ±0.4 < 0.001
Angiographic information:
Vessels with > 50% DS 2.4 ±1.4 2.3 ±1.4 2.4 ±1.3 2.7 ±1.1 0.691
Type of procedure:
PCI + POBA 4 (2.9) 1 (1.4) 3 (5.7) 0 (0) 0.314
PCI + limus-DES 118 (86.8) 62 (86.1) 45 (84.9) 11 (100) 0.307
PCI + BMS 6 (4.4) 3 (4.2) 3 (5.7) 0 (0) 0.700
OMT 8 (5.9) 5 (6.9) 3 (5.7) 0 (0) 0.657
No. of implanted stents 1.3 ±0.6 1.2 ±0.6 1.5 ±0.8 1.0 ±0.5 0.060
Length of stents 26.5 ±17.8 23.6 ±1.4 31.2 ±22.4 22.4 ±14.8 0.066
Values are means ± SD or n (%). BMS – bare-metal stent, DES – drug-eluting stent, CABG – coronary artery bypass graft, eGFR – estimated glomerular filtration rate, 
HGB – hemoglobin, INR – international normalized ratio, LMWH – low molecular weight heparin, MI – myocardial infarction, PCI – percutaneous coronary interven-
tion, PLT – platelets, POBA – plain old balloon angioplasty, OMT – optimal medical treatment, TT – triple therapy, VKA – vitamin K antagonist. Group 1 comprises 
patients with warfarin/acenocoumarol; group 2 comprises patients with rivaroxaban/dabigatran; group 3 comprises patients with low molecular weight heparin. 
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and the remaining 11 (8.7%) were given LMWH + DAPT. 
The CHA2DS2-VASc and HAS-BLED scores were similar 
across the study subgroups (p = 0.64 and p = 0.64 re-
spectively) and are shown in Table I.
Baseline and periprocedural characteristics were 
similar between the groups discharged on various forms 
of TT (Table I). Patients admitted for MI with in-hospi-
tal bleeding complications were more likely to be given 
LMWH as part of TT than other anticoagulation drugs, 
but the difference is not statistically significant (18.2% 
vs. 8.3% vs. 3.8% respectively, p = 0.23).
TT modifications after hospital discharge
Within 1 month after discharge, among the 11 pa-
tients discharged on LMWH + DAPT, the initial TT was 
replaced by VKA + DAPT in 5 and by NOAC + DAPT in 4. 
Two patients remained on LMWH + DAPT indefinitely.
On follow-up, 87 (66.9%) patients reported some 
sort of alteration in their antithrombotic regimen. Out of 
those, 11 (8.5%) reported a switch of one antithrombotic 
drug for another. Detailed information on drug switch-
es is described in Figure 1. Seventy-six (58.5%) patients 
terminated TT: 59 (45.4%) prematurely and 17 (13.1%) 
as recommended by the treating cardiologist. Detailed 
information on alterations in the TT including time of ter-
Table II. In-hospital thrombotic and bleeding complications grouped by type of anticoagulation drug patient 
received as part of TT on discharge. Blood transfusion and access site hematoma predisposed to prescribing 
LMWH on discharge (group 3)
Parameter Total
(n = 136)
Group 1
(n = 72)
Group 2
(n = 53)
Group 3
(n = 11)
Fisher’s exact test
between subgroups, p
Thrombotic complications: 9 (6.6) 6 (8.4) 2 (3.8) 1 (9.1) 0.480
Thrombus in heart chambers 5 (3.7) 3 (4.2) 1 (1.9) 1 (9.1) 0.346
In-stent thrombosis 3 (2.2) 3 (4.2) 0 (0) 0 (0) 0.428
PE 1 (0.7) 0 (0) 1 (1.9) 0 (0) 0.471
Major bleeding: 31 (22.8)    
GI bleeding 7 (5.1) 3 (4.2) 2 (3.7) 2 (18.2) 0.152
Hg drop > 2 g/l 27 (19.8) 10 (13.9) 14 (26.4) 3 (27.3) 0.172
Transfusion 4 (2.9) 1 (1.4) 1 (1.9) 2 (18.2) 0.033
NMCR bleeding: 16 (11.8)    
Access site hematoma 11 (8.1) 7 (5.1) 1 (1.9) 3 (27.3) 0.018
Hematuria 7 (5.1) 3 (4.2) 3 (5.7) 1 (9.1) 0.476
URT bleedings 4 (2.9) 1 (1.4) 2 (3.8) 1 (9.1) 0.277
Minor bleeding: 45 (33.1)    
Nosebleeds 36 (26.5) 20 (27.8) 13 (24.5) 3 (27.3) 0.956
Other 13 (9.6) 9 (12.5) 4 (7.5) 0 (0) 0.602
Values are n (%). Other minor bleeding complications included microscopic hematuria and bruising. TT – triple therapy, VKA – vitamin K antagonist, DAPT – dual 
antiplatelet therapy, NOAC – novel oral anticoagulant, LMWH – low molecular weight heparin, PE – pulmonary embolism, GI – gastrointestinal, Hg – hemoglobin, 
URT – upper respiratory tract. Group 1 comprises patients with warfarin/acenocoumarol; group 2 comprises patients with rivaroxaban/dabigatran; group 3 comprises 
patients with low molecular weight heparin.
Figure 1. Switches between anticoagulation drugs. 
Each line represents 1 patient. Three patients 
switched from dabigatran to VKA (1 – mechanical 
valve, 1 – financial reasons, 1 – unknown reasons), 
3 switched from VKA to rivaroxaban (2 – labile INR, 
1 – enrolled in a rivaroxaban drug trial), 2 switched 
from dabigatran to rivaroxaban (1 – allergic reaction 
to dabigatran, 1 – unknown reasons), 2 switched 
from rivaroxaban to VKA (1 – bleeding complica-
tions, 1 – unknown reasons) and 1 switched from 
VKA to dabigatran (unknown reasons)
LMWH – low molecular weight heparin, VKA – vitamin K antagonists.
LMWH
Rivaroxaban Rivaroxaban
Dabigatran Dabigatran
VKA VKA
 Disacharge Follow-up
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mination, number of drugs terminated and type of drugs 
terminated is presented in Figure 2.
Thrombotic and bleeding complications in the 
follow-up period
The mean follow-up was 10.2 ±4.2 months (range: 
3–18). Detailed information about final antithrombotic 
regimens was available for 130 (95.6%) of the patients. 
Six (4.6%) were lost to follow-up (5 from the VKA group, 
1 from the NOAC group), but according to the national 
Medical Insurance Database (eWUŚ) they were alive and 
no hospital admissions were recorded as of March 1st, 
2016. 
During follow-up, thrombotic events occurred in 16 
(12.3%) patients, any bleeding (major, NMCR and mi-
nor) occurred in 45 (34.6%). Eleven (8.5%) deaths were 
recorded. Seven of them resulted from thrombotic com-
plications (2 mesenteric emboli, 3 MIs, 2 sudden cardiac 
deaths), 1 from bleeding complication (ICH) and 3 from 
other causes (1 pneumonia, 1 cardio-respiratory insuffi-
ciency, 1 sudden, not well-determined death). 
Nine (6.9%) non-fatal thrombotic complications were 
observed (1 IS, 7 MIs and 1 PE).
Out of 10 patients who suffered an MI during fol-
low-up, in-stent thrombosis occurred in 7 (according to 
the adopted definition, 6 were definite and 1 was pos-
sible).
There was no significant difference in the occurrence 
of thrombotic complications between patients on various 
forms of TT (Table III).
Interestingly, only 4 out of 10 MIs occurred in patients 
who had terminated any of the TT drugs prematurely: 
3 in patients who had terminated any antiplatelet agent 
and 1 in a patient who terminated OAC (Table IV). There 
was no significant difference in occurrence of MI between 
patients who terminated any TT drug prematurely and 
those who did not (6.8% vs. 8.5%, p = 0.72). One IS was 
recorded and it occurred in a patient who had terminated 
the use of ASA prematurely and subsequently switched 
from rivaroxaban to dabigatran due to an allergic reac-
tion. We noted no significant difference in the appear-
ance of any thrombotic (both fatal and non-fatal) com-
plication between those patients who terminated any of 
the drugs prematurely and those who did not (11.9% vs. 
12.7%, p = 0.54), as well as between subgroups of pa-
tients on various forms of TT (Table IV).
The number of any bleeding events (major, NMCR and 
minor) was 45 (34.6%). The frequency of any bleeding 
was not different between patients who prematurely 
terminated any of the drugs as compared to those who 
did not. Fourteen major bleeding events (6 GI, 6 URT and 
2 ICH, one of which was fatal) were recorded. All major 
bleeding complications appeared in patients actively tak-
ing all three drugs, and there was a significant difference 
in the major bleeding occurrence between those patients 
who continued TT vs. those who terminated any of the 
drugs prematurely (18.6% vs. 4.2%, p = 0.008). Addition-
ally, 13 (10%) NMCR bleeding events occurred. There is 
no statistically significant difference in the occurrence 
of NMCR in patients who terminated any of the TT drug 
vs. those who did not (8.4% vs. 11.2%, p = 0.60). Minor 
bleeding occurred in 32 (24.6%) patients and included 
bruising, trace of blood on handkerchief, and prolonged 
bleeding after a small injury. No significant difference in 
Switched to another drug
Planned termination
Premature termination
Any alternation
A
B
C
Termination of VKA
Termination of NOAC
Termination 
of P2Y12-inhibitor
Termination of ASA
Termination of 3 drugs
Termination of 2 drugs
Termination of 1 drug
8.50%
6.50%
1.50%
13.10%
10.50%
18.50%
45.40%
35.40%
66.90%
36.20%
38.50%
Figure 2. Alterations in therapy. A – any alterna-
tion (87 patients, 66.9%), premature termina-
tion (59 patients, 45.4%), planned termination  
(17 patients, 13.1%) and switch to another drug 
(11 patients, 8.5%). B – termination of 1 drug  
(50 patients, 38.5%), 2 drugs (24 patients, 18.5%) 
or 3 drugs (2 patients, 1.5%). C – termination of 
ASA (47 patients, 36.2%), P2Y12 inhibitors (46 pa-
tients, 35.4%), VKA (5 patients, 6.5%) and NOAC 
(6 patients, 10.5%). Seventy-two patients had VKA 
prescribed and 55 patients had NOAC prescribed
ASA – acetylsalicylic acid, NOAC – novel oral anticoagulant,  
VKA – vitamin K antagonist.
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minor bleeding events was found between patients who 
terminated any TT drug prematurely vs. those who did 
not (25.4% vs. 23.9%, p = 0.85). 
Cumulative event-free survival Kaplan-Meier curves 
showed the overall event-free survival of 96.1% at 
1 month and 67.2% at 6 months in patients on active TT 
(Figure 3). The respective 1- and 6-month survival free 
from death were 100% and 89.1%, from thrombotic 
events 99.2% and 85.9%, and from major bleeding 96.9% 
and 84.4% (Figure 3).
Discussion
The present study was designed to assess the safety 
and complication rate of TT in patients with AF and PCI 
Table III. Thrombotic and bleeding complications during long-term observation grouped by type of anticoagu-
lation drug patient received as part of TT. Group 1 patients had a significantly higher rate of PE compared to 
group 2 patients
Parameter Total
(n = 136)
Group 1
(n = 77)
Group 2
(n = 57)
Group 3
(n = 2)
c2 group 1
vs. group 2
Fisher’s exact test  
between subgroups, p
Thrombotic complications: 16 (11.8) 11 (14.3) 5 (8.8) 0 (0) 0.330 0.552
MI 10 (7.4) 6 (7.8) 4 (7.0) 0 (0) 0.866 0.999
In-stent thrombosis 7 (5.1) 5 (6.5) 2 (3.5) 0 (0) 0.443 0.729
IS 1 (0.7) 0 (0) 1 (1.8) 0 (0) 0.243 0.434
PE 5 (3.7) 5 (6.5) 0 (0) 0 (0) 0.050 0.139
Bleeding: 45 (33.1) 28 (36.4) 17 (29.8) 0 (0) 0.428 0.519
Major 14 (10.3) 10 (13.0) 4 (7.0) 0 (0) 0.246 0.512
NMCR 13 (9.6) 9 (11.7) 4 (7.0) 0 (0) 0.366 0.637
Minor 32 (23.5) 18 (23.4) 14 (24.6) 0 (0) 0.874 0.999
Values are n (%). TT – triple therapy, MI – myocardial infarction, IS – ischemic stroke, PE – peripheral embolism (including mesenteric embolism – pulmonary embo-
lism), NMCR – non-major clinically relevant. Group 1 comprises patients with warfarin/acenocoumarol, group 2 comprises patients with rivaroxaban/dabigatran, 
group 3 comprises patients with low molecular weight heparin.
Table IV. Thrombotic and all fatal complications grouped by premature termination of various TT drugs. Early 
termination of any TT drug was associated with lower risk of major bleeding
Parameter Total
N = 130
Premature  
termination  
of any AA
51 (39.2)
No premature 
termination  
of any AA
79 (60.8)
P-value
c2
Premature 
termination  
of OAC
5 (3.8)
No premature 
termination  
of OAC
125 (96.2)
P-value
c2
P-value  
between  
subgroups*
All deaths: 11 (8.5) 3 (5.9) 8 (10.1) 0.396 0 (0) 11 (8.8) 0.488 0.750
Thrombotic 7 (5.4) 3 (5.9) 4 (5.1) 0.840 0 (0) 7 (5.6) 0.586 0.999
Bleeding 1 (0.8) 0 (0) 1 (1.3) 0.420 0 (0) 1 (0.8) 0.841 0.999
Other 3 (2.3) 0 (0) 3 (3.8) 0.159 0 (0) 3 (2.4) 0.726 0.443
Thrombo-embolic 
complications:
16 (12.3) 6 (11.8) 10 (12.7) 0.880 1 (20) 15 (12) 0.593 0.999
MI 10 (7.7) 3 (5.9) 7 (8.9) 0.534 1 (20) 9 (7.2) 0.291 0.649
In-stent  
thrombosis
7 (5.4) 2 (3.9) 5 (6.3) 0.553 0 (0) 7 (5.6) 0.586 0.841
IS 1 (0.8) 1 (2.0) 0 (0) 0.212 0 (0) 1 (0.8) 0.841 0.454
PE 5 (3.8) 2 (3.9) 3 (3.8) 0.971 0 (0) 5 (4) 0.648 0.999
Bleeding: 45 (34.6) 19 (37.3) 26 (32.9) 0.611 3 (60) 42 (33.6) 0.224 0.247
Major 14 (10.8) 6 (11.8) 8 (10.1) 0.769 0 (0) 14 (11.2) 0.428 0.001
NMCR 13 (10) 5 (9.8) 8 (10.1) 0.952 0 (0) 13 (10.4) 0.447 0.406
Minor 32 (24.6) 13 (25.5) 19 (24.1) 0.852 3 (60) 29 (22.3) 0.061 0.999
Values are n (%). AA – antiplatelet agent, OAC – oral anticoagulant, MI – myocardial infarction, IS – ischemic stroke, PE – peripheral embolism. *Fisher’s exact test 
between groups of patients who terminated any antiplatelet agent prematurely vs. those who terminated OAC prematurely vs those who terminated any antiplatelet 
agent and OAC prematurely.
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recruited consecutively between October 1st 2014 and 
September 30th 2015, whose anticoagulation regimen on 
discharge was prescribed following the recent 2014 ESC 
guidelines on AF in patients presenting with MI and/or 
undergoing PCI [8].
Similarly to other studies, in the present one approx-
imately 5% of the patients undergoing PCI have been re-
ceiving OAC for AF [4, 13–15]. That is a significant group 
of patients, yet it remains unclear how to treat them in 
terms of both peri-procedural and long-term anticoagula-
tion. Out of 136 recruited subjects with AF, approximately 
a half presented with MI on admission. The optimal an-
ticoagulant strategy in these patients is also unknown, 
and little research has been published on this matter [4, 
16–18].
OAC selection as a part of TT following PCI
In our study no clear pattern was observed in terms 
of assigning a patient to a certain type of TT. In-hospital 
bleeding complications in the form of access-site hema-
toma and need for blood transfusions significantly more 
frequently guided physicians to give patients LMWH on 
discharge. Most patients discharged on LMWH were 
reassigned for VKA or NOAC during 4 weeks following 
discharge. We did not determine any other statistically 
significant predictors for choosing particular OAC as part 
of TT. We rather conclude that, with the guidelines be-
ing vague in this regard, the decision of the type of anti-
thrombotic drug as part of TT is left to the discretion of 
the leading physician and the preference of the patient, 
and LMWH seems to be considered by cardiologists as 
a safer option in patients with in-hospital bleeding com-
plications. 
The convenience of NOACs with fixed oral dosing and 
no need to monitor the anticoagulation effect, as well as 
very few interactions with other drugs or food products, 
seems to be a better choice for most patients, but in Pol-
ish reality NOACs are still associated with a significantly 
higher monthly cost of the therapy compared to VKA, 
and that could be the reason why only about 40% of the 
patients were given NOACs. We believe that the patient’s 
preference was a  major factor in the decision-making 
process.
Older guidelines prefer BMS implantation (particular-
ly over first generation DES) in TT patients to shorten the 
necessity of TT [6]; however, this attitude faces serious 
limitations related to high risk of recurrent stenosis ap-
proaching 44% in patients with diabetes, renal failure, 
infection, PCI in small coronary vessels, long lesions and 
bifurcations [19]. Therefore, the probable benefit gained 
from the short period of TT in this group of patients is 
significantly limited by the restenosis rate. On the other 
hand, 2nd generation DES have a  favorable outcome in 
terms of restenosis and a  relatively short period of re-
quired TT (3–6 months). The Biolimus DES introduced 
recently allows an even shorter time of TT. In a LEADERS 
Free ACS Study comparing the Biolimus DES with a BMS, 
at 12-month follow-up, treatment with the Biolimus DES 
was more effective (clinically driven target-lesion revas-
cularization 3.9 vs. 9.0%, p = 0.009) and safer (cumula-
tive incidence of cardiac death, MI, or definite or probable 
stent thrombosis 9.3 vs. 18.5%, p = 0.001), with signifi-
cantly lower rates of cardiac mortality (3.4 vs. 6.9%, p = 
0.049) and MI (6.9 vs. 13.8%, p = 0.005) [20].
There is still a gap in the guidelines concerning MI pa-
tients left without PCI and qualified for optimal medical 
treatment. In the present study 8 patients were included 
in the analysis even though no PCI was performed – they 
were all AF patients admitted for MI in which TT was 
implemented and were facing the same risks of TT as 
the rest of the cohort. According to guidelines on STEMI 
[21], DAPT should be administered for up to 12 months 
in these patients. The recent guidelines do not address 
that issue [8]. 
Long-term observation
Faza et al. [22] observed that in median 4 months 
follow-up 26.7% out of 999 patients developed bleed-
ing on TT (defined as at least 3 g/dl hemoglobin drop). 
Our study showed a slightly higher number of bleeding 
complications (34.6% of any bleeding) noted in longer 
follow-up, but a broader definition of bleeding was ad-
opted. In a meta-analysis [23] of 9 studies comparing TT 
to DAPT alone, the authors found that the latter was cor-
related with much lower bleeding complications during 
1-year follow-up (OR = 0.51 for major bleeding). No dif-
ference in thrombotic event rate was found.
With regard to all bleeding, as well as major, NMCR 
and minor, we did not find any significant differences 
across different TT schemes in our study. The fact of TT 
itself was the major risk factor for major bleeding. More-
Figure 3. Kaplan-Meier curves showing event-free 
survival of patients on active triple therapy (TT). 
No patients with TT lasting 12 months were free 
from complications
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over, the fact of early discontinuation of any anticoagu-
lant was associated with the reduction of major bleeding 
incidents, and had no impact on thrombotic event occur-
rence. Indeed, the early termination of any component of 
TT was frequent and concerned about 45% of patients, 
including ASA termination in 36.2%, P2Y12 inhibitor in 
35.4%, VKA in 6.5% and NOAC in 10.5% of patients. 
Moreover, D’Ascenzo et al. compared 6 studies in 
which OAC + clopidogrel + ASA or OAC + clopidogrel was 
used. OAC + clopidogrel was associated with a major re-
duction of bleeding without affecting the rate of throm-
botic events [23]. 
In another study concerning older patients with AF 
and MI undergoing PCI, TT was associated with greater 
risk of bleeding requiring hospitalization (HR = 1.61) as 
well as ICH (HR = 2.04). Risk of thrombotic events was 
similar in both groups [24]. 
In a Danish registry [25], 315 (0.8%) out of 40 812 pa-
tients admitted due to MI were on TT. The yearly incidence 
of bleeding was 12.0% for TT, whereas it was 3.7% for aspi-
rin with clopidogrel and 2.6% for aspirin alone. In a recent 
study, Constantinos et al. did not find any differences in 
bleeding risk in patients with TT lasting 1 month as com-
pared to TT longer than 1 month [26]. In a large nationwide 
registry of 40 812 patients hospitalized with MI, the risk 
of subsequent hospitalizations for bleeding increased with 
the number of antithrombotic drugs used, being 1.8-fold 
in patients on VKA and aspirin, 3.5-fold in patients on VKA 
and clopidogrel, and 4-fold in patients on TT, with numbers 
needed to harm of 45.4, 15.2, and 12.5, respectively [3, 25]. 
Our study showed a significant increase in risk of major 
bleeding on continuous TT compared to patients who had 
terminated any TT drug (p = 0.008).
The data above may lead to an assumption that the 
risks of continuing TT for more than 1 month may out-
weigh the benefits and should be individually considered. 
This is reflected in the latest ESC guidelines suggesting 
shortening the TT to a  minimum by discontinuing one 
antiplatelet agent, which in most cases could be reduced 
to 1 month. The other recommendations include: the use 
of new generation DES as preferred over BMS, avoidance 
of novel P2Y12 inhibitors (prasugrel, ticagrelor) as part of 
DAPT, the use of the radial artery as the preferred access 
site, and broad use of PPIs to reduce the risk of GI bleed-
ing [5, 8]. In patients who had been taking OAC before 
PCI, the drug they had been using should be continued 
as part of TT. If VKA is part of TT, the recommended INR 
should be within 2.0–2.5 for the time of TT with the ther-
apeutic range > 70%. If NOAC is the drug of choice, a re-
duced dose of NOAC (i.e. 110 mg dabigatran BID, 15 mg 
rivaroxaban OD) should be prescribed for the duration of 
TT [8, 27]. 
As proven above, this group of patients is particular-
ly challenging, as they remain at high risk of thrombotic 
complications both because of AF and the implement-
ed stent and they should be adequately protected. The 
pathophysiology of clot formation in the fibrillating atri-
um (low sheer stress) is believed to be different from the 
formation of a clot within the stent (high sheer stress). 
Research shows that serum clotting factors play the 
leading role in clot formation in an AF setting, whereas 
platelet activation is believed to be crucial in formation 
of thrombus within the stent [25, 28–31]. Therefore it 
seems necessary to merge OAC therapy with DAPT in 
those patients. Our study showed that patients taking 
NOACs as part of TT are better protected from peripheral 
embolism than those on VKA. This reflects similar find-
ings in pivotal NOAC trials such as RE-LY with dabigatran 
(relative risk of primary outcome in the form of stroke or 
systemic embolism for higher dose dabigatran vs. VKA 
0.66, 95% CI: 0.53–0.82) and ROCKET-AF with rivarox-
aban (hazard of primary outcome in form of stroke or 
systemic embolism for rivaroxaban vs VKA 0.79; 95% CI: 
0.66–0.96) [32, 33].
Indeed, the most unfavorable combination of TT was 
VKA + DAPT, which was associated with higher risk of pe-
ripheral embolic events. The possible explanation of this 
phenomenon might be an insufficient therapeutic target 
for VKA with recommended INR 2.0–2.5, labile INR and pa-
tients’ compliance. Interestingly, VKA is still preferred over 
NOACs by US guidelines in the setting of AF and PCI [34]. 
Study limitations
The study was performed retrospectively, which 
posed challenges in regard to data quality and consis-
tency. The follow-up period is relatively short, and the 
number of study participants is small. For the majority of 
endpoints the power of the study is limited.
Moreover, the TT in studied patients was introduced 
at different stages of the disease – some were admitted 
to our department and had already been taking an anti-
coagulation drug, whereas others were treatment naïve 
and only started the TT during or after hospitalization. 
To eliminate bias stemming from the above-mentioned 
differences, a prospective study would be of value. The 
study did not analyze the time in therapeutic range (TTR) 
in patients taking VKA; thus effective anticoagulation 
was not documented.
Conclusions
Our real-life all-comers evaluation showed that about 
5% of patients undergoing PCI required TT. There is still 
a lot of uncertainty and inconsistency in terms of the op-
timal management of the patients. The 10-month mor-
tality of those patients was high (in our study 8.1%), and 
so was the thrombotic event rate (12.3%). Nevertheless, 
the occurrence of thrombotic events does not seem to 
be related to premature termination of any antiplatelet 
agents. Over 30% of patients suffered from bleeding 
complications, and continuation of TT was associated 
with a higher rate of major bleeding. A substantial num-
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ber of patients reported alterations to their TT, with as 
many as 44.6% of the patients terminating their therapy 
prematurely for various reasons. Our study has a relative-
ly short follow-up period, and the number of study par-
ticipants is not big enough, so further research is needed 
on this subject to gather more data that would help de-
termine the right way of treating these very challenging, 
high-risk patients.
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